TrialThe British journal of dermatology2022

The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.

Margitta Worm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.